Aspen Neuroscience, Inc. develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative diseases. The company's develops ANPD001, an investigational single-dose, autologous dopaminergic neuronal precursor cell (DANPC) therapy for Parkinson's disease. It operates in the…
| Métrica | ASPE | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 58.3% | — |
| Operating Margin | — | -31.5% | — |
| Net Margin | — | -30.9% | — |
| FCF Margin | — | -10.6% | — |
| ROE | — | -36.3% | — |
| ROA | — | -29.8% | — |
| Current Ratio | — | 2.68 | — |
| Debt / Equity | — | 0.28 | — |
Aspen Neuroscience, Inc. cotiza a 13.61 USD y tiene una capitalización bursátil de $396M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud